From a biomolecular point of view, near one half of tumours ALK positive treated with crizotinib develop a secondary resistance mutation as gatekeeper mutation like L1196M, which gives a further tumoural ‘gain of function’ under the selective pressure of crizotinib exposure. The gene discussed is ALK; the disease is neoplasm.